425: Sonnet BioTherapeutics Delays Merger Vote

Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to December 2, 2025, to allow more time for voting on its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.

Summary

• The special meeting of stockholders, originally scheduled for November 18, 2025, has been adjourned to December 2, 2025, at 9:00 a.m. Eastern Time.
• The purpose of the adjournment is to provide stockholders additional time to vote on the proposed business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC, and other related proposals.
• The company needs to solicit additional votes to meet the required threshold for transaction approval, which is a majority of all outstanding shares.
• More than 95% of the shares that have already been voted on the Business Combination proposal are in favor.
• HSI's shares have received approval for listing by Nasdaq, contingent upon the consummation of the proposed business combination.
• The Board of Directors unanimously recommends that stockholders vote FOR all proposals on the agenda.

Sentiment

Score: 4

Explanation: While a high percentage of votes cast are in favor, the necessity to adjourn the meeting due to insufficient overall votes for the required threshold introduces uncertainty and a delay in a critical strategic transaction. The Nasdaq approval for HSI is positive, but the underlying issue of securing full shareholder support remains.

Positives

• Over 95% of the shares that have been voted on the Business Combination proposal are in favor, indicating strong support among participating stockholders.
• Hyperliquid Strategies Inc.'s shares have been approved for listing by Nasdaq, which is a positive step towards the consummation of the proposed business combination.

Negatives

• The special meeting for the proposed business combination has been delayed, indicating that the company had not yet secured sufficient votes to meet the required threshold (a majority of all outstanding shares) for approval as of the original meeting date.

Risks

• Failure to obtain the required majority of all outstanding shares for the business combination approval could jeopardize the transaction, leading to potential strategic and financial repercussions for Sonnet BioTherapeutics Holdings, Inc.

Future Outlook

The proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC is expected to proceed, with HSI's securities anticipated to be listed on Nasdaq upon consummation of the transaction. Management remains focused on finalizing the business combination and is optimistic about the potential of the Hyperliquid blockchain.

Management Comments

• "The Company's Board of Directors continues to believe that all of the proposals contained in the proxy statement are advisable and in the best interests of the Company's stockholders to consider and act upon."
• "While we regret the delay, we are pleased that of the stockholders who have voted on the transaction proposal to date, more than 95% have voted in favor of the Business Combination." David Schamis, Chief Executive Officer of HSI.
• "Further good news is that HSI's shares have been approved for listing by Nasdaq." David Schamis, Chief Executive Officer of HSI.
• "While we remain focused on finalizing the Business Combination, we are also incredibly excited about the opportunity and the potential of the Hyperliquid blockchain." David Schamis, Chief Executive Officer of HSI.

Industry Context

This announcement reflects a common challenge in corporate mergers and acquisitions, where securing sufficient shareholder approval can sometimes require additional time and solicitation efforts, even when a significant majority of votes cast are in favor. The proposed combination involves a biotechnology company (Sonnet) and a blockchain strategies company (Hyperliquid), indicating a potential diversification or strategic shift for Sonnet, or a reverse merger scenario where Hyperliquid gains a public listing.

Stakeholder Impact

• Shareholders: Required to cast their votes by the new meeting date; the delay introduces uncertainty regarding the timing and ultimate approval of the business combination, which could impact share value.
• Management: Must continue efforts to solicit votes and finalize the transaction.
• Hyperliquid Strategies Inc. (HSI) and Rorschach I LLC: Experience a delay in their planned business combination and public listing.

Next Steps

• Stockholders are encouraged to vote on the proposed business combination and other proposals by the reconvened meeting date.
• The reconvened Special Meeting of stockholders will be held on December 2, 2025, at 9:00 a.m. Eastern Time.
• Consummation of the proposed business combination transaction.
• Listing of HSI securities on Nasdaq upon consummation of the business combination.

Key Dates

Recommendation

The delay in the special meeting for the business combination introduces uncertainty, despite a high percentage of votes already cast being in favor. Investors should hold to await the outcome of the reconvened meeting on December 2, 2025, as the successful completion of the merger and HSI's Nasdaq listing could be a positive catalyst, while failure to secure approval would be a significant negative.

Keywords

Sonnet BioTherapeutics, Hyperliquid Strategies, Rorschach I LLC, Business Combination, Merger, Special Meeting, Stockholder Vote, Nasdaq Listing, Biotechnology, Oncology, FHAB platform